Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1987 1
1988 5
1989 5
1990 3
1991 2
1992 11
1993 5
1994 5
1995 5
1996 5
1997 11
1998 7
1999 15
2000 10
2001 31
2002 20
2003 27
2004 30
2005 30
2006 28
2007 28
2008 42
2009 30
2010 43
2011 44
2012 40
2013 57
2014 90
2015 116
2016 134
2017 132
2018 198
2019 197
2020 165
2021 40
Text availability
Article attribute
Article type
Publication date

Search Results

1,360 results
Results by year
Filters applied: . Clear all
Page 1
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A. Pardanani A. Am J Hematol. 2019 Mar;94(3):363-377. doi: 10.1002/ajh.25371. Epub 2019 Jan 2. Am J Hematol. 2019. PMID: 30536695 Free article. Review.
DIAGNOSIS: The major criterion is presence of multifocal clusters of abnormal MC in the bone marrow. Minor diagnostic criteria include elevated serum tryptase level, abnormal MC CD25 expression, and presence of KITD816V mutation. ...Treatment of SM-AHN primarily tar …
DIAGNOSIS: The major criterion is presence of multifocal clusters of abnormal MC in the bone marrow. Minor diagnostic criteria …
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.
Rajkumar SV. Rajkumar SV. Am J Hematol. 2016 Jul;91(7):719-34. doi: 10.1002/ajh.24402. Am J Hematol. 2016. PMID: 27291302 Free PMC article. Review.
Multiple myeloma accounts for approximately 10% of hematologic malignancies.The diagnosis requires 10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE): CRAB (hypercalcemia, renal fai …
Multiple myeloma accounts for approximately 10% of hematologic malignancies.The diagnosis requires 10% clonal bone marrow plas …
Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state.
Saadeh SS, Litzow MR. Saadeh SS, et al. Expert Rev Hematol. 2018 Mar;11(3):195-207. doi: 10.1080/17474086.2018.1433030. Epub 2018 Feb 7. Expert Rev Hematol. 2018. PMID: 29376437 Review.
Allogeneic hematopoietic stem cell transplant (allo-HSCT) has an important role in management of acute lymphoblastic leukemia (ALL). ...The integration of targeted and immunotherapies in the peri-transplant period holds potential for improved outcomes....
Allogeneic hematopoietic stem cell transplant (allo-HSCT) has an important role in management of acute lymphoblastic leukemia (ALL). …
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.
Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V. Gonsalves WI, et al. Bone Marrow Transplant. 2019 Mar;54(3):353-367. doi: 10.1038/s41409-018-0264-8. Epub 2018 Jul 9. Bone Marrow Transplant. 2019. PMID: 29988062 Free PMC article. Review.
Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical adv …
Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell …
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.
Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Savani BN, Veys PA, Bredeson CN, Giralt SA, LeMaistre CF. Majhail NS, et al. Biol Blood Marrow Transplant. 2015 Nov;21(11):1863-1869. doi: 10.1016/j.bbmt.2015.07.032. Epub 2015 Aug 7. Biol Blood Marrow Transplant. 2015. PMID: 26256941 Free PMC article.
Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed in the United States annually. ...Indications for HCT continue to evolve as research refines the role for HCT in established indications and identifies emerging indications where HCT may …
Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed in the United States annually. ...Indications …
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management.
Rajkumar SV. Rajkumar SV. Am J Hematol. 2018 Aug 16;93(8):981-1114. doi: 10.1002/ajh.25117. Am J Hematol. 2018. PMID: 30400719 Free PMC article.
DISEASE OVERVIEW: Multiple myeloma accounts for approximately 10% of hematologic malignancies. DIAGNOSIS: The diagnosis requires 10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE): …
DISEASE OVERVIEW: Multiple myeloma accounts for approximately 10% of hematologic malignancies. DIAGNOSIS: The diagnosis requires 10% clonal …
Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT.
Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, Bredeson C, Fenske TS, Smith SM, Sureda A, Moskowitz A, Friedberg JW, Inwards DJ, Herrera AF, Kharfan-Dabaja MA, Reddy N, Montoto S, Robinson SP, Abutalib SA, Gisselbrecht C, Vose J, Gopal A, Shadman M, Perales MA, Carpenter P, Savani BN, Hamadani M. Kanate AS, et al. JAMA Oncol. 2019 May 1;5(5):715-722. doi: 10.1001/jamaoncol.2018.6278. JAMA Oncol. 2019. PMID: 30816957 Free PMC article.
IMPORTANCE: Maintenance therapies are often considered as a therapeutic strategy in patients with lymphoma following autologous hematopoietic cell transplantation (auto-HCT) to mitigate the risk of disease relapse. With an evolving therapeutic landscape, where novel drugs …
IMPORTANCE: Maintenance therapies are often considered as a therapeutic strategy in patients with lymphoma following autologous hematopoieti …
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. Giralt S, et al. Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30. Biol Blood Marrow Transplant. 2015. PMID: 26428082 Free PMC article.
In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with multiple myeloma (MM) is well established, the role of high-dose therapy with autologou …
In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as …
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Chaudhry HM, Bruce AJ, Wolf RC, Litzow MR, Hogan WJ, Patnaik MS, Kremers WK, Phillips GL, Hashmi SK. Chaudhry HM, et al. Biol Blood Marrow Transplant. 2016 Apr;22(4):605-616. doi: 10.1016/j.bbmt.2015.09.014. Epub 2015 Sep 26. Biol Blood Marrow Transplant. 2016. PMID: 26409924 Free article. Review.
Oral mucositis (OM) is a debilitating early adverse effect of allogeneic hematopoietic stem cell transplantation (HSCT). The intensity of the conditioning regimen correlates with the incidence and severity of OM, but no studies have analyzed this relationship among various …
Oral mucositis (OM) is a debilitating early adverse effect of allogeneic hematopoietic stem cell transplantation (HSCT). The intensit …
Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation.
El Helou G, Razonable RR. El Helou G, et al. Expert Opin Drug Saf. 2019 Nov;18(11):1017-1030. doi: 10.1080/14740338.2019.1662787. Epub 2019 Sep 6. Expert Opin Drug Saf. 2019. PMID: 31478398 Review.
Introduction: Human cytomegalovirus (HCMV) is a major contributor of morbidity and mortality, and its management is essential for the successful outcome of solid organ and hematopoietic stem cell transplantation. Areas covered: This review discusses the safety profiles of …
Introduction: Human cytomegalovirus (HCMV) is a major contributor of morbidity and mortality, and its management is essential for the succes …
1,360 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page